Trial Profile
Study of talabostat + docetaxel [Taxotere; sanofi-aventis] versus docetaxel in stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Jul 2007
Price :
$35
*
At a glance
- Drugs Talabostat (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Point Therapeutics
- 02 Jan 2006 New trial record.